Do Posaconazole Tablets Carry Hypertension, Hypokalemia Risks?

SAN DIEGO — Rebecca Wittenberg, PharmD, spoke to MPR at IDWeek 2017 about the research paper she co-authored on posaconazole and the risks of hypertension and hypokalemia. Higher serum posaconazole concentrations have been associated with improved clinical responses, however higher serum and tissue levels are likely to reveal previously undescribed toxicity as adverse events attributed to ‘off target’ effects are observed. 

Read more about this study here.

For more infectious disease news coverage from the IDWeek 2017, check MPR’s IDWeek page for the latest updates.